In today’s briefing:
- Saint Bella IPO: Revenue Growth Re-Accelerated, 34 Postpartum Centers Were Opened In 2024
- BBLG: Now is the Time to Look at BBLG
- SanBio Co Ltd (4592 JP): Akuugo Shipments Expected To Commence In 2QFY26, New Credit Line In Place
- TELO: Data Shows Potential Treatment for Age-Related Diseases
Saint Bella IPO: Revenue Growth Re-Accelerated, 34 Postpartum Centers Were Opened In 2024
- Saint Bella, a premium postpartum care and recovery provider, moves toward Hong Kong IPO following strong +43% y/y revenue growth in 2024.
- The company is uniquely positioned in premium segment under Saint Bella, Bella Isla and Baby Bella brands.
- I believe Saint Bella has the potential to become one of the key postpartum care and recovery providers targeting HNW, high income and young middle class families in China
BBLG: Now is the Time to Look at BBLG
- Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal fusion using the recombinant human protein known as NELL-1/DBX, or NB1.
- The company continues with human trials, and we are looking forward to the initial results and suggest investors consider investing ahead of the result release.
SanBio Co Ltd (4592 JP): Akuugo Shipments Expected To Commence In 2QFY26, New Credit Line In Place
- SanBio Co Ltd (4592 JP) successfully completed three commercial production runs to accumulate inventories in preparation for launch. The earliest possible timing for shipment is expected to be 2QFY26.
- During FY25, SanBio did not generate any revenue. The successful launch and shipments are likely to have only a minimal impact on the financial performance of the company in FY26.
- SanBio has a cash runway through FY26. Further, in, company entered into a new committed credit line agreement (¥1B) with Mizuho Bank.
TELO: Data Shows Potential Treatment for Age-Related Diseases
- Telomir Pharmaceuticals is a preclinical stage company focused on reversing biological aging and degenerative diseases.
- The company announced preclinical test results that showed Telomir-1 reversed multiple symptoms in an animal model of Wilson’s disease.
- These results provide further proof of the potential of Telomir-1 to reduce aging-related diseases.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
